Erlotinib in lung cancer. Pao W, Ladanyi M, Miller VA, Lung Cancer Oncogenome Group (2005) N Engl J Med 353: 1739-41; author reply 1739-41 Treatment of Ménétrier's disease with a monoclonal antibody against the epidermal growth factor receptor. Burdick JS, Chung E, Tanner G, Sun M, Paciga JE, Cheng JQ, Washington K, Goldenring JR, Coffey RJ (2000) N Engl J Med 343: 1697-701 ERBB2 inhibition and heart failure. Cote GM, Sawyer DB, Chabner BA (2013) N Engl J Med 368: 876 Beyond exon 2--the developing story of RAS mutations in colorectal cancer. Berlin J (2013) N Engl J Med 369: 1059-60 Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) N Engl J Med 358: 1109-17 ERBB2 inhibition and heart failure. Cote GM, Sawyer DB, Chabner BA (2012) N Engl J Med 367: 2150-3 Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J (2012) Nature 487: 505-9 Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Nature 483: 100-3 FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL (2011) Nature 471: 523-6 The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B (2012) Nature 486: 537-40 Helicobacter pylori: gastric cancer and beyond. Polk DB, Peek RM (2010) Nat Rev Cancer 10: 403-14 Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Pao W, Chmielecki J (2010) Nat Rev Cancer 10: 760-74 Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ (1990) Cell 61: 1147-55 The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ (2012) Cell 149: 146-58 Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC (1995) Science 269: 230-4 New driver mutations in non-small-cell lung cancer. Pao W, Girard N (2011) Lancet Oncol 12: 175-80 ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Arteaga CL, Engelman JA (2014) Cancer Cell 25: 282-303 Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Arteaga CL, Baselga J (2004) Cancer Cell 5: 525-31 EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT (2012) Cancer Cell 22: 304-17 HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL (2006) Cancer Cell 10: 25-38 EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Arteaga CL (2006) Cancer Cell 9: 421-3 EGFR signalling controls cellular fate and pancreatic organogenesis by regulating apicobasal polarity. Löf-Öhlin ZM, Nyeng P, Bechard ME, Hess K, Bankaitis E, Greiner TU, Ameri J, Wright CV, Semb H (2017) Nat Cell Biol 19: 1313-1325 Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Singh B, Coffey RJ (2014) Annu Rev Physiol 76: 275-300 Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) J Clin Oncol 23: 7889-96 Molecular on/off switch. Milton DT, Riely GJ, Pao W, Miller VA, Kris MG, Heelan RT (2006) J Clin Oncol 24: 4940-2 HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA (2017) J Clin Oncol 35: 446-464 Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry. Hameed O, Chhieng D, Adams AL (2008) J Clin Oncol 26: 1571 Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H (2010) J Clin Oncol 28: 4616-20 Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH (2008) J Clin Oncol 26: 1472-8 Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL, American Society of Clinical Oncology, College of American Pathologists (2007) J Clin Oncol 25: 5418-25 EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. Arteaga CL (2003) J Clin Oncol 21: 289s-291s Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. Pao W, Miller VA (2005) J Clin Oncol 23: 2556-68 High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM (2007) J Clin Oncol 25: 3644-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.